Omega-3 Supplements Boost Longevity Proteins in Type 2 Diabetics Taking Glimepiride

This completed clinical trial examined whether omega-3 fatty acid supplementation could enhance key longevity proteins in type 2 diabetic patients already receiving standard medication. The study specifically targeted irisin and sirtuin-1, two proteins increasingly recognized for their roles in metabolic health and cellular aging processes.

Seventy participants with type 2 diabetes were enrolled in this controlled trial. All participants were taking glimepiride, a standard diabetes medication, at doses of 2-3mg daily. The intervention group additionally received 1000mg of omega-3 fatty acids daily, while researchers monitored multiple health markers including blood glucose, lipid profiles, and the target proteins.

Irisin, often called the "exercise hormone," helps regulate metabolism, muscle function, and energy expenditure. Sirtuin-1 activates cellular repair mechanisms and has been linked to longevity pathways in multiple studies. Both proteins decline with age and metabolic dysfunction, making them important targets for health optimization.

The trial ran from January 2019 to May 2020, providing sufficient time to observe meaningful changes in these biomarkers. While specific results weren't detailed in the available summary, the study's completion suggests researchers successfully gathered data on omega-3's effects on these longevity-associated proteins.

For health-conscious individuals, this research addresses a practical question: can readily available omega-3 supplements provide anti-aging benefits beyond their known cardiovascular effects? The focus on diabetic patients is particularly relevant, as this population faces accelerated aging processes and could benefit significantly from interventions that address both metabolic control and cellular health simultaneously.